Endometrial neoplasms

Researchers are testing an oral drug called AL58805, which blocks two cancer-growth proteins, PI3K and mTOR, in adults with advanced endometrial, cervical, soft tissue sarcoma, or breast cancers that have worsened after at least one standard treatment. Participants receive AL5880…

Researchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …

This Phase 3 trial tests a new biologic drug (PF-08634404) plus chemotherapy against the approved drug Keytruda plus chemotherapy in 600 women with advanced or recurrent pMMR endometrial cancer. The goal is to see if the new combination helps patients live longer without their ca…

This trial tests whether adding orlistat, a weight-loss drug that blocks fat absorption, to standard progestin therapy can improve treatment response in young women (45 or younger) with early-stage endometrial cancer or atypical endometrial hyperplasia who have low progesterone r…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

Many cancer trials require patients to have specific molecular markers, so researchers test large numbers of people to find the few who qualify. This study evaluates FATHOM, an AI system that reads clinical trial records and routine tumor slides to predict which patients carry th…

This observational study will test a new molecular test called CISENDO, which looks at DNA methylation in cells from a routine cervical smear. The goal is to see if it can accurately detect endometrial cancer or precancerous lesions in women at medium-to-high risk. Researchers wi…